TITAN is an ongoing randomised, controlled, open-label Phase III trial comparing PREZISTA co-administered with ritonavir (600/100 mg b.i.d.) versus lopinavir/ritonavir (400/100 mg b.i.d) in treatment-experienced, lopinavir naïve HIV-1 infected adult patients.